Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants

BWX Lim; N Li; S Mahale; S McInerny; M Zethoven; SM Rowley; J Huynh; T Wang; JEA Lee; M Friedman; L Devereux; RJ Scott; EK Sloan; PA James; IG Campbell

Journal article

Somatic inactivation of breast cancer predisposition genes in tumors associated with pathogenic germline variants

BWX Lim, N Li, S Mahale, S McInerny, M Zethoven, SM Rowley, J Huynh, T Wang, JEA Lee, M Friedman, L Devereux, RJ Scott, EK Sloan, PA James, IG Campbell

Journal of the National Cancer Institute | Published : 2023

DOI: 10.1093/jnci/djac196

Download PDF

Abstract

Background: Breast cancers (BCs) that arise in individuals heterozygous for a germline pathogenic variant in a susceptibility gene, such as BRCA1 and BRCA2, PALB2, and RAD51C, have been shown to exhibit biallelic loss in the respective genes and be associated with triple-negative breast cancer (TNBC) and distinctive somatic mutational signatures. Tumor sequencing thus presents an orthogonal approach to assess the role of candidate genes in BC development. Methods: Exome sequencing was performed on paired normal-breast tumor DNA from 124 carriers of germline loss-of-function (LoF) or missense variant carriers in 15 known and candidate BC predisposition genes identified in the BEACCON case-con..

View full abstract

University of Melbourne Researchers

Related Projects (3)

IDENTIFICATION OF GENES IN INVOLVED IN THE PREDISPOSITION, INITIATION AND PROGRESSION OF BREAST AND OVARIAN CANCER

Our knowledge of the number and nature of the genes involved in breast and ovarian cancer is limited. To rapidly define the critical breast ..

Common genomic variants and familial breast cancer

Breast Cancer is a common disease with up to 20% of cases associated with a family history. This project aims to assess the contribution of ..

LIFEPOOL IS A POWERFUL AND UNIQUE RESOURCE THAT WILL FACILITATE THE DEVELOPMENT AND VALIDATION OF NEW IDEAS FOR TREATMENT AND EARLY DETECTION OF BREAST CANCER

Grants

Awarded by Cancer Council Victoria

Funding Acknowledgements

This work was supported by the National Breast Cancer Foundation (IF-15-004, IGC and PAJ), Cancer Australia/National Breast Cancer Foundation (PdCCRS_1107870, IGC and PAJ), Cancer Australia/National Breast Cancer Foundation (PdCCRS_1188547, IGC and PAJ), the Victorian Cancer Agency (Tumor Stream Grant, PAJ), the National Health and Medical Research Council of Australia (GNT1023698, PAJ; GNT1041975, IGC) and Cancer Australia (PdCCRS_1188547, IGC, PAJ, and EKS). EKS is supported by the National Health and Medical Research Council GNT114749, the <EM><STRONG> </STRONG></EM>National Breast Cancer Foundation IIRS-20-025 and Cancer Council Victoria Grants-in-Aid. NL is supported by Cancer Council Victoria.